PT  - JOURNAL ARTICLE
AU  - Anna L Guyatt
AU  - Catherine John
AU  - Alexander T Williams
AU  - Nick Shrine
AU  - Nicola Reeve
AU  - SpiroMeta consortium
AU  - Ian P Hall
AU  - Louise V Wain
AU  - Nuala A Sheehan
AU  - Frank Dudbridge
AU  - Martin D Tobin
TI  - Mendelian randomisation analyses of eosinophils and other blood cell types in relation to lung function and disease
AID  - 10.1101/2020.07.09.20148726
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.07.09.20148726
4099  - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20148726.short
4100  - http://medrxiv.org/content/early/2020/07/11/2020.07.09.20148726.full
AB  - Background Eosinophils are granulocytes associated with airway inflammation in respiratory disease. Eosinophil production and survival is controlled by interleukin-5: anti-interleukin-5 agents reduce asthma and COPD exacerbation frequency, and response correlates with baseline eosinophil counts. However, causal relationships between eosinophils and other respiratory phenotypes are less studied.Methods We investigated causality between eosinophils and: lung function, acute exacerbations of COPD (AECOPD), asthma-COPD overlap (ACO), moderate-to-severe asthma, and respiratory infections. We performed Mendelian randomization (MR) using 151 genetic variants from genome-wide association studies of blood eosinophil counts in UK Biobank/INTERVAL, and respiratory data from UK Biobank, using MR methods relying on different assumptions for validity. Multivariable MR using eight blood cell type exposures was performed for outcomes showing evidence of causation by eosinophils.Findings There was evidence that higher eosinophils reduce FEV1/FVC and FEV1 (weighted median estimator, SD change FEV1/FVC per SD eosinophils: −0.054 [95%CI −0.078,−0.029]. There was also evidence that eosinophils cause ACO (weighted median OR 1.44 [95%CI 1.19,1.74]), and asthma (weighted median OR 1.50 [95%CI 1.23,1.83]). Multivariable MR for FEV1/FVC, FEV1, ACO and asthma suggested that eosinophils were the cell type with the most important effect. Causal estimates of individual variants were heterogeneous, which may arise from pleiotropy.Interpretation We found evidence that eosinophils reduce lung function, and increase ACO and asthma risk, on average over the set of genetic variants studied. Eosinophils appear to be causal determinants of fixed airflow obstruction among individuals with features of both asthma and COPD.Funding Wellcome, BHF, MRC, BBSRC CASE studentship with GSK, GSK/BLF.Competing Interest StatementMDT and LVW receive funding from GSK for collaborative research projects outside of the submitted work. IPH has funded research collaborations with GSK, Boehringer Ingelheim and Orion.Funding StatementALG is funded by internal fellowships at the University of Leicester from the Wellcome Trust Institutional Strategic Support Fund (204801/Z/16/Z) and the BHF Accelerator Award (AA/18/3/34220). CJ holds a Medical Research Council Clinical Research Training Fellowship (MR/P00167X/1). ATW is funded by a BBSRC CASE studentship with GSK. LVW holds a GSK/British Lung Foundation Chair in Respiratory Research. MDT is supported by a Wellcome Trust Investigator Award (WT202849/Z/16/Z). MDT and LVW have been supported by the MRC (MR/N011317/1). MDT and IPH hold NIHR Senior Investigator Awards. The research was also supported by BREATHE - The Health Data Research Hub for Respiratory Health (MC_PC_19004). The research was partially supported by the NIHR Leicester Biomedical Research Centre and the NIHR Nottingham Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in the design of the Mendelian randomization analyses. ALG and MDT were involved in all stages of study development and delivery, and MDT had full access to all data in the study and final responsibility for the decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research used published summary data from published genome-wide association studies, plus data from UK Biobank. This particular research was conducted using the UK Biobank Resource under Application Number 648. UK Biobank has ethical approval from the UK National Health Service (NHS) National Research Ethics Service (Ref 11/NW/0382).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis manuscript uses summary-level GWAS data. Lung function GWAS summary statistics as well as the blood cell GWAS summary statistics are available from the EBI GWAS catalog (https://www.ebi.ac.uk/gwas/). Other GWAS summary statistics are available from the authors on request. https://www.ebi.ac.uk/gwas/